Eunice Asomaning, MD
Family Medicine · Danielson, CTNPI 1962758508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 422 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$927
- GSK$886
- Boehringer Ingelheim$559
- AstraZeneca$511
- Lilly USA, LLC$419
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,028100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $1,870 |
| Novo Nordisk | 53 | $927 |
| GSK | 43 | $886 |
| Boehringer Ingelheim | 33 | $559 |
| AstraZeneca | 25 | $511 |
| Lilly USA, LLC | 21 | $419 |
| Otsuka America Pharmaceutical, Inc. | 19 | $343 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $336 |
| Amgen | 10 | $215 |
| Novartis | 10 | $206 |
| Astellas Pharma US Inc | 9 | $205 |
| Corcept Therapeutics | 6 | $162 |
| Pfizer | 9 | $161 |
| Scilex Pharmaceuticals Inc. | 6 | $128 |
| Merck | 7 | $124 |
| Sanofi-aventis U.S. LLC | 7 | $112 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $95 |
| Biohaven Pharmaceuticals, Inc. | 4 | $94 |
| Lundbeck LLC | 4 | $87 |
| Actelion Pharmaceuticals US, Inc. | 3 | $78 |
| Vanda Pharmaceuticals Inc. | 3 | $77 |
| Braeburn Inc. | 3 | $64 |
| Cranial Technologies, Inc | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Currax Pharmaceuticals LLC | 3 | $44 |
| Indivior Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $33 |
| Eisai Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
How this compares
$8,046 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 129 | $114,899 |
| EliquisApixaban | 109 | $114,225 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $79,777 |
| TrulicityDulaglutide | 23 | $44,930 |
| MounjaroTirzepatide | 35 | $34,635 |
| FarxigaDapagliflozin Propanediol | 27 | $31,808 |
| ProliaDenosumab | 13 | $22,203 |
| RybelsusSemaglutide | 18 | $21,261 |
| VraylarCariprazine Hcl | 12 | $17,289 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $15,575 |
| OzempicSemaglutide | 14 | $13,277 |
| LinzessLinaclotide | 14 | $11,605 |
| JanuviaSitagliptin Phosphate | 14 | $7,363 |
| ZoloftSertraline Hcl | 13 | $6,424 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $5,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $559 | $114,899129 claims |
| PfizerEliquis | $161 | $114,225109 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $886 | $95,35173 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $419 | $79,56558 claims |
| Novo NordiskRybelsus, Ozempic | $927 | $34,53832 claims |
| AstraZenecaFarxiga | $511 | $31,80827 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,870 | $31,07751 claims |
| AmgenProlia | $215 | $22,20313 claims |
| MerckJanuvia | $124 | $7,36314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Danielson
- Anthony PurcellDanielson$14K
- Alan RuizDanielson$5K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.